Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Leukemia 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Juvenile 2Inflammation 2Asthma 2Wilms Tumor 1Vasculitis 1Uveitis 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Respiratory Distress Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lupus Nephritis 1Lung Injury 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Immunoglobulin Light-chain Amyloidosis 1Granulomatosis with Polyangiitis 1Fatigue Syndrome, Chronic 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Bronchiolitis Obliterans 1Blast Crisis 1

Interventions

Etanercept 2NVP-QAV680 1Beclomethasone 1Azithromycin 1Amoxicillin-Potassium Clavulanate Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Asthma × Etanercept × Clear all
NCT00001893 2017-07-02

Study of TNFR:Fc (Enbrel) in the Treatment of Asthma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
150 enrolled

Asthma

NCT00141791 2009-08-07

Study Evaluating Etanercept in Moderate to Severe Asthma

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
120 enrolled

Asthma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡